Cureety supports patients, healthcare professionals and researchers in their fight against cancer.

Our certified Software as a Medical Device enables us to improve patient care, simplify clinical workflows and collect new data for researchers.

6 000+

PATIENTS

1 000 +

HEALTHCARE PROFESSIONALS

80+

HEALTHCARE INSTITUTIONS

An application designed with and for healthcare teams

Patients or their clinical team can use the platform independently, on their computer, tablet or cell phone. At regular intervals, patients complete a monitoring questionnaire specific to their treatment or protocol.

After analysis of the responses by our medical device, an alert is generated for the care teams, and an appropriate guidance message is sent to the patient, along with therapeutic advice to help manage grade 1 and 2 adverse events.

Patient information content and digital supportive care are also accessible via the app.

For the few patients who cannot or do not wish to use the application, a phone monitoring module is available. 

A member of the care team can enter the patients responses to the questionnaire during a phone call with the patient. 

Following analysis of the responses by our medical device, an alert is generated for the care teams. The entire patient cohort can thus be remotely monitored via our platform.

The “OK-Chemo” module collates patients’ reported toxicities and blood test results one or two days before their scheduled appointments.

This is used to pre-validate patients’ chemotherapy appointments at the outpatient department.

Precise symptom monitoring and proactive management​

Scheduling a visit in day hospital

Consultation support

The benefits of remote monitoring in oncology

Detecting symptoms before consultations

Improved quality
of life

Reduced risk of hospitalization

Improved life expectancy

The American STAR (Symptom Tracking and Reporting) study of 766 cancer patients, conducted by Dr Basch and his team, has demonstrated that the efficacy of anti-cancer treatments is not the only parameter for improving life expectancy and quality of life for patients with advanced cancer (1).

A remote monitoring solution enables patients to be closely monitored between consultations. Digital tools can facilitate monitoring and help improve patients’ quality of life, reduce emergency hospitalizations and improve life expectancy (1, 2, 3).

(1) Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial ; Ethan Basch et al. ; Journal of Clinical Oncology 2016 34:6, 557-565 ; doi:10.1200/JCO.2015.63.0830​

(2) Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318(2):197-198. DOI: 10.1001/jama.2017.7156

(3) Denis F, Basch E, Septans A, et al. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. JAMA. 2019;321(3):306-307. DOI: 10.1001/jama.2018.18085

Our publications

Posters

ASCO 2021: The benefits of the Cureety platform for the patient care pathway in oncology

Improving cancer patient care with a digital telemonitoring platform: The ConnectPatientToDoctor study
Helissey, Duverger, et al. Journal of Clinical Oncology 2021;39:15_suppl:1581. doi: 10.1200/JCO.2021.39.15_suppl.1581

ESMO 2021 : The benefits of the Cureety platform for monitoring older patients in oncology

Effectiveness of a digital telemonitoring platform for elderly cancer patient (EP) care
Helissey, Duverger, et al. Annals Oncol 2021;32(S5):S1187. doi: 10.1016/j.annonc.2021.08.1675

ASCO GU 2022: Patient-reported outcomes are an early indicator of prostate cancer patient survival

Electronic patient-reported outcomes are a promising predictive factor of prostate cancer patient survival: The Protecty study
Helissey, Riviere, et al. Journal of Clinical Oncology 2022 Feb 20;40(6_suppl):76. doi:10.1200/JCO.2022.40.6_suppl.076

ASCO 2022: Patient-reported outcomes are an early indicator of cancer progression in older patients

Early patient-reported outcomes are a promising predictive factor of cancer progress and outcome in older patients: The EPROFECY study.
Helissey, Riviere, et al. Journal of Clinical Oncology 2022 June 1;40(16_suppl):12045. doi:10.1200/JCO.2022.40.16_suppl.12045

ASCO 2023: High performance of the Cureety TechCare algorithm in assessing the health status of cancer patients

A study to assess the diagnostic performance of a digital remote monitoring tool for cancer patients: the POSITEA-VA study.
Parnot, Montestruc. Journal of Clinical Oncology 2023 Jun 1;41(16_suppl):1605. doi:10.1200/JCO.2023.41.16_suppl.1605

Scientific publications

JMIR 2022: High levels of cancer patient participation and satisfaction using the remote monitoring platform Cureety

The Use of Telemedicine in Cancer Clinical Trials: Connect-Patient-to-Doctor Prospective Study
Meghiref, Parnot, et al. JMIR Cancer 2022 Jan 27;8(1):e31255. doi:10.2196/31255

IJC 2022: The benefits of the Cureety platform for monitoring older patients in oncology

Effectiveness of a digital telemonitoring platform for cancer care of older patients: The ConnectElderlyPatientToDoctor study
Rivière, Brureau,et al. Int J Cancer. 2023 Feb 1;152(3):504-510. doi:10.1002/ijc.34196

Frontiers 2023: Remote monitoring of prostate cancer patients with the Cureety platform

Effectiveness of electronic patient reporting outcomes, by a digital telemonitoring platform, for prostate cancer care: the Protecty study
Helissey, Parnot, et al. Front. Digit. Health 2023 May 8;5:1104700. doi:10.3389/fdgth.2023.1104700

They're already using Cureety

Hear from our care teams

"The app allows us to maintain a very human relationship with our patients and to be able to respond quickly to their needs."

Dr. Noémie STUDDER, support care and patient pathways manager

“The Cureety platform allows me to manage my patients much more easily and quickly.“​

Joana ROSE, coordinating nurse

"We use Cureety as a remote monitoring tool for all patients in the Porte de Saint-Cloud clinical center, for all types of patients, all types of location and all types of treatments, from chemotherapy to immunotherapy, targeted therapy or radiotherapy."

Dr. Thomas FEUTREN, radiotherapist oncologist